Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Operating Expenses (2022 - 2025)

Bioregenx has reported Operating Expenses over the past 4 years, most recently at $1.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 93.27% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $2.7 million, down 88.75%, while the annual FY2025 figure was $2.7 million, 88.75% down from the prior year.
  • Operating Expenses for Q4 2025 was $1.3 million at Bioregenx, up from $434856.0 in the prior quarter.
  • Over five years, Operating Expenses peaked at $18.6 million in Q4 2024 and troughed at $13474.0 in Q3 2022.
  • A 4-year average of $2.1 million and a median of $703800.5 in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 22460.15% in 2023 and later plummeted 93.27% in 2025.
  • Year by year, Operating Expenses stood at $14449.0 in 2022, then surged by 3980.42% to $589580.0 in 2023, then soared by 3061.5% to $18.6 million in 2024, then plummeted by 93.27% to $1.3 million in 2025.
  • Business Quant data shows Operating Expenses for BRGX at $1.3 million in Q4 2025, $434856.0 in Q3 2025, and $459715.0 in Q2 2025.